To explore the clinical application of anti-SENP1 for the treatment of platinum-resistant ovarian cancer patients, we found that SENP1 siRNA or inhibitor Momordin Ic exhibits remarkable synergistic effect with cisplatin on platinum-resistant ovarian cancer. This evidence concerns the gene SENP1 and ovarian carcinoma.